All In Biotech

Drug Trial Radar · NCT00590837

Adding Lomustine to Chemotherapy in Older Patients With Acute Myelogenous Leukemia (AML), and Allogeneic Transplantation for Patients From 60 to 65 Years Old

Randomized Prospective Study of Adding Lomustine to Idarubicin and Cytarabine for Induction and Post-remission Chemotherapy in Older Patients With Acute Myeloid Leukaemia, and Feasibility of Allogeneic Transplantation for Patients From 60 to 65 Years Old

Last checked: Nov 20, 2026Latest source record: Apr 2, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 459 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

459

Actual

Start

Feb 2008

Primary completion

Dec 2012

Study completion Dec 2013

Sponsor

Lead sponsor
University Hospital, BordeauxAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 11, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter randomized trial comparing induction therapy (IC: Idarubicin and Cytarabine, 5 + 7) to ICL (the same drugs plus lomustine (CCNU), 200 mg/m2 orally at day 1). Patients in complete remission (CR) will then receive a post-remission schedule with or without lomustine according to randomization. Patients from 60 to 65 years old will be proposed to reduced conditioning allogeneic transplantation after first consolidation.

Conditions

  • Acute Myeloid Leukemia

Interventions

  • LomustineDrug

    Induction: chemotherapy + lomustine (CCNU), 200 mg/m2 orally at day 1. Consolidation: chemotherapy + lomustine (CCNU), 80 mg orally at day 1. Reinductions: chemotherapy + lomustine (CCNU), 40 mg orally at day 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: 1 year

Locations

32 sites in 1 country. Site status is shown where the registry gives one.

  • Services maladies du sang, cancérologie, Hôpital Sud, CHU Amiens

    Amiens, France

  • Service des maladies du sang, Centre Hospitalier Universitaire d'Angers

    Angers, France

  • Service Hématologie, Centre Hospitalier Annecy

    Annecy, France

  • C.H Victor Dupouy

    Argenteuil, France

  • Service Médecine Interne, Onco-Hématologie, Maladies Infectieuses, Hôpital Henri Duffaut, Centre Hospitalier Avignon

    Avignon, France

  • Service Hématologie, Centre Hospitalier de la Côte Basque

    Bayonne, France

  • Service Hématologie, Hôpital Minjoz

    Besançon, France

  • Unité Hématologie, Centre Hospitalier Blois

    Blois, France

  • Service des maladies du sang - Hôpital Haut-Lévêque

    Bordeaux - Pessac, France

  • Service Hématologie, Hôpital Dr Duchenne

    Boulogne-sur-Mer, France

  • Service Hématologie, Hôpital Augustin Morvan

    Brest, France

  • Service Hématologie et Thérapie cellulaire, Pavillon Villemin Pasteur, CHU Clermont-Ferrand

    Clermont-Ferrand, France

  • Service Oncologie - Hématologie, Hôpital Pasteur, Centre Hospitalier Colmar

    Colmar, France

  • Service Hématologie Clinique, CHU Dijon Hôpital des enfants

    Dijon, France

  • Service Hématologie Clinique, Hôpital Michallon, CHU de Grenoble

    Grenoble, France

  • Service Onco-Hématologie 3, Institut Paoli Calmettes

    Marseille, France

  • Service Hématologie Oncologie, CHR Metz-Thionville

    Metz, France

  • Service Hématologie Oncologie, Hôpital Lapeyronie, CHU de Montpellier

    Montpellier, France

  • Département d'hématologie, Hôpital E.Muller, Centre Hospitalier de Mulhouse

    Mulhouse, France

  • Service Hématologie Clinique, CHU -Hôtel Dieu

    Nantes, France

  • Service Hématologie Clinique, Hôpital Archet 1

    Nice, France

  • Service Médecine B - Unité Onco-hématologique, CHU Caremeau

    Nîmes, France

  • Service Oncologie Médicale, Hôpital de la Source

    Orléans, France

  • Unité d'Hématologie, Hôpital Cochin

    Paris, France

  • Service Hématologie, CHG Saint Jean

    Perpignan, France

  • Service Hématologie Clinique, Hôpital Robert Debre

    Reims, France

  • Service Hématologie Clinique, Hôpital Pontchaillou

    Rennes, France

  • Service d'Hématologie, Institut de Cancérologhie de la Loire

    Saint Priez En Jarez, France

  • Département d'Hématologie et d'Oncologie, Hôpital CHRU de Hautepierre

    Strasbourg, France

  • Service Hématologie, Hôpital Purpan

    Toulouse, France

  • Service Hématologie Clinique, Hôpital Bretonneau

    Tours, France

  • Service Hématologie - Médecine Interne, Hôpitaux de Brabois

    Vandœuvre-lès-Nancy, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.